Keymed Biosciences Narrows Loss in H1; CFO Steps Down

MT Newswires Live

2025/08/26

Keymed Biosciences (HKG:2162) narrowed its attributable loss to 78.8 million yuan in the first half of 2025 from 336.7 million yuan a year prior, a Tuesday Hong Kong bourse filing said.

Loss per share for the biopharmaceutical firm was 0.30 yuan, down from 1.29 yuan in the year-ago period.

Revenue for the interim period increased 812% to 498.8 million yuan from 54.7 million yuan in the corresponding period of the last year.

In separate news, Yanrong Zhang resigned as the firm's chief financial officer effective immediately to devote more time to other commitments. Zhang will now act as a consultant for the company.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2562341527"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2562341527\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2562341527?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-26 21:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2562341527","market":"fut","top_or_hot":-1,"title":"Keymed Biosciences Narrows Loss in H1; CFO Steps Down","media":"MT Newswires Live","content":"<html><body><p> Keymed Biosciences (HKG:2162) narrowed its attributable loss to 78.8 million yuan in the first half of 2025 from 336.7 million yuan a year prior, a Tuesday Hong Kong bourse filing said.</p><p>Loss per share for the biopharmaceutical firm was 0.30 yuan, down from 1.29 yuan in the year-ago period.</p><p>Revenue for the interim period increased 812% to 498.8 million yuan from 54.7 million yuan in the corresponding period of the last year.</p><p>In separate news, Yanrong Zhang resigned as the firm's chief financial officer effective immediately to devote more time to other commitments. Zhang will now act as a consultant for the company.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Keymed Biosciences Narrows Loss in H1; CFO Steps Down</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKeymed Biosciences Narrows Loss in H1; CFO Steps Down\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-08-26 21:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Keymed Biosciences (HKG:2162) narrowed its attributable loss to 78.8 million yuan in the first half of 2025 from 336.7 million yuan a year prior, a Tuesday Hong Kong bourse filing said.</p><p>Loss per share for the biopharmaceutical firm was 0.30 yuan, down from 1.29 yuan in the year-ago period.</p><p>Revenue for the interim period increased 812% to 498.8 million yuan from 54.7 million yuan in the corresponding period of the last year.</p><p>In separate news, Yanrong Zhang resigned as the firm's chief financial officer effective immediately to devote more time to other commitments. Zhang will now act as a consultant for the company.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02162","symbol_name":"康诺亚-B","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2562341527","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2562341527","pubTimestamp":1756215501,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Keymed Biosciences  narrowed its attributable loss to 78.8 million yuan in the first half of 2025 from 336.7 million yuan a year prior, a Tuesday Hong Kong bourse filing said.Loss per share for the biopharmaceutical firm was 0.30 yuan, down from 1.29 yuan in the year-ago period.Revenue for the interim period increased 812% to 498.8 million yuan from 54.7 million yuan in the corresponding period of the last year.In separate news, Yanrong Zhang resigned as the firm's chief financial officer effective immediately to devote more time to other commitments. Zhang will now act as a consultant for the company.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"02162":"康诺亚-B"},"translate_title":"Keymed Biosciences上半年亏损收窄；首席财务官辞职","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02162":0.9},"content_text":"Keymed Biosciences (HKG:2162) narrowed its attributable loss to 78.8 million yuan in the first half of 2025 from 336.7 million yuan a year prior, a Tuesday Hong Kong bourse filing said.Loss per share for the biopharmaceutical firm was 0.30 yuan, down from 1.29 yuan in the year-ago period.Revenue for the interim period increased 812% to 498.8 million yuan from 54.7 million yuan in the corresponding period of the last year.In separate news, Yanrong Zhang resigned as the firm's chief financial officer effective immediately to devote more time to other commitments. Zhang will now act as a consultant for the company.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"executive,express","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}